Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Vernakalant Hydrochloride
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : Advanz Pharma
Deal Size : $76.0 million
Deal Type : Acquisition
Advanz Pharma Limited Closes Acquisition of Specialty Pharmaceutical Company Correvio Pharma Corp
Details : Advanz Pharma believes that Correvio's niche portfolio, consisting of an established brand, and two growing, patent-protected brands, plus a pipeline of potential product launches, are highly complementary to its current priorities and future focus.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : $76.0 million
May 27, 2020
Lead Product(s) : Vernakalant Hydrochloride
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : Advanz Pharma
Deal Size : $76.0 million
Deal Type : Acquisition
Lead Product(s) : Tirofiban
Therapeutic Area : Hematology
Study Phase : Approved FDF
Sponsor : Hong Kong Teson Pharma
Deal Size : $3.5 million
Deal Type : Agreement
Correvio Partners with Hong Kong Teson Pharma Limited
Details : The investment vehicle, which LSP claims is the largest of its type in Europe, is bigger than the VC shop’s three previous life science funds combined.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : $3.0 million
March 10, 2020
Lead Product(s) : Tirofiban
Therapeutic Area : Hematology
Highest Development Status : Approved FDF
Sponsor : Hong Kong Teson Pharma
Deal Size : $3.5 million
Deal Type : Agreement
Reset All
